2. Academic Validation
  3. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF

HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF

  • Cancer Cell. 2011 Jan 18;19(1):31-44. doi: 10.1016/j.ccr.2010.11.009.
Charlotte Rolny 1,  Massimiliano Mazzone,  Sònia Tugues,  Damya Laoui,  Irja Johansson,  Cathy Coulon,  Mario Leonardo Squadrito,  Inmaculada Segura,  Xiujuan Li,  Ellen Knevels,  Sandra Costa,  Stefan Vinckier,  Tom Dresselaer,  Peter Åkerud,  Maria De Mol,  Henriikka Salomäki,  Mia Phillipson,  Sabine Wyns,  Erik Larsson,  Ian Buysschaert,  Johan Botling,  Uwe Himmelreich,  Jo A Van Ginderachter,  Michele De Palma,  Mieke Dewerchin,  Lena Claesson-Welsh,  Peter Carmeliet
Affiliations

Affiliation

  • 1 Uppsala University, Department of Genetics and Pathology, Rudbeck Laboratory, 75185 Uppsala, Sweden.
PMID: 21215706 DOI: 10.1016/j.ccr.2010.11.009
Abstract

Polarization of tumor-associated macrophages (TAMs) to a proangiogenic/immune-suppressive (M2-like) phenotype and abnormal, hypoperfused vessels are hallmarks of malignancy, but their molecular basis and interrelationship remains enigmatic. We report that the host-produced histidine-rich glycoprotein (HRG) inhibits tumor growth and metastasis, while improving chemotherapy. By skewing TAM polarization away from the M2- to a tumor-inhibiting M1-like phenotype, HRG promotes antitumor immune responses and vessel normalization, effects known to decrease tumor growth and metastasis and to enhance chemotherapy. Skewing of TAM polarization by HRG relies substantially on downregulation of placental growth factor (PLGF). Besides unveiling an important role for TAM polarization in tumor vessel abnormalization, and its regulation by HRG/PLGF, these findings offer therapeutic opportunities for Anticancer and antiangiogenic treatment.

Figures